Clinical Trials
31 trialsA Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Tongji Hospital
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Hadassah Medical Organization
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Alexion Pharmaceuticals, Inc.
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Fred Hutchinson Cancer Center
Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
Tongji NADs Cohort
Tongji Hospital
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
University of Texas Southwestern Medical Center
Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
Tianjin Huanhu Hospital
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Alexion Pharmaceuticals, Inc.
Biobank For MS And Other Demyelinating Diseases
Accelerated Cure Project for Multiple Sclerosis
CAR-AID
RenJi Hospital
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Tianjin Medical University General Hospital
NAD-AIRE
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
Xuanwu Hospital, Beijing
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)
University of Bern
Biomarkers in Autoimmune Disease of Nervous System
Tongji Hospital
CARTinNS
Tongji Hospital
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
NIDBase
Xuanwu Hospital, Beijing
SONICS
University of Texas Southwestern Medical Center
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Alexion Pharmaceuticals, Inc.
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
Neuromed IRCCS
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
State University of New York at Buffalo
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Alexion Pharmaceuticals, Inc.
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Johns Hopkins University
Central Pain Study for ABX-1431
Abide Therapeutics
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Johns Hopkins University
STRIVE
Guy's and St Thomas' NHS Foundation Trust
Safety and Tolerability of Rituximab in Neuromyelitis Optica
University of California, San Francisco
Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Office of Rare Diseases (ORD)